Hologic (NASDAQ:HOLX) is a medical technology company focused on improving women’s health through early detection and treatment, including digital mammography and pap testing. In March, the company paid $1.65 billion to acquire Cynosure, a leader in aesthetic laser treatment. While early results from Cynosure have been disappointing, we believe Hologic has the management depth to turn its performance around. Meanwhile, we expect Hologic’s pipeline of innovative new products to widen its lead in women’s health.
From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third quarter 2017 commentary.
